# BSX — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-06-14. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 6.5 · Fundamentals 7.8 · Technicals 3.2 · Growth 7 · Risk 7

## Summary

Boston Scientific has been cut in half from ~$109 to $46.91 amid WATCHMAN/EP guidance cuts, yet the underlying business still posted Q1'26 revenue of $5.20B with 69.4% gross margins and $1.34B net income — a stark disconnect between fundamentals and tape. With forward P/E of 12.6x, RSI at 29, analyst target of $76.57, and the Penumbra/Thunderbolt catalyst closing, this looks like an oversold quality compounder where the market has likely overshot, though knife-catching risk is real until price stabilizes above $50.

## Price targets (12-month horizon)

- Bear: $38.00
- Base: $62.00
- Bull: $78.00

## News context

The signal: Truist cut PT from $85 to $64 but kept Buy, explicitly citing WATCHMAN growth concerns from management commentary — this confirms the bear case has real fundamental basis, not just sentiment. Counterbalancing this, FDA cleared Penumbra's Thunderbolt thrombectomy platform on June 12, and Boston Scientific's pending Penumbra acquisition gives BSX direct exposure to a newly-approved stroke device that one analyst estimates contributes ~$100M in incremental revenue. SeekingAlpha framed the setup as 'market pricing a broken compounder, we see a reset one' — this is the crux of the debate.

Net read: the WATCHMAN/EP issue is the real risk, but at $46.91 with $100M of incremental Penumbra revenue layering in and a still-growing core business, much of the bad news appears priced. The market news (crypto/Trump/Pokemon) is irrelevant noise for BSX.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/bsx-ai-stock-forecast-cfb91584cb11f21e200f27d6f17669c9
- AI-generated; model outputs can be wrong. Not financial advice.